A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 4, 2006, Pages 379-388

  Schneeweiss, Sebastian ^a,b,c   Maclure, Malcolm ^a,b,c   Dormuth, Colin R ^a,b,c   Glynn, Robert J ^a,b,c   Canning, Claire ^a,b,c   Avorn, Jerry ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGED; ARTICLE; CANADA; CONSULTATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG SUBSTITUTION; DRUG UTILIZATION; ECONOMIC EVALUATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; INSURANCE; MALE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT FAILURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BRITISH COLUMBIA; COST SAVINGS; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES FOR THE AGED; HOSPITALIZATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; OMEPRAZOLE; PHYSICIAN'S PRACTICE PATTERNS; SULFOXIDES;

EID: 33645890572     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.12.304     Document Type: Article

References (45)

1. Heffler S., Smith S., Keehan S., Clemens M.K., Zezza M., and Truffer C. Health spending projections through 2013. Health Aff (Millwood) Suppl:W4 (2004) 79-93
2. Strunk B.C., and Ginsburg P.B. Tracking health care costs. trends turn downward in 2003. Health Aff (Millwood) Suppl:W4 (2004) 354-362
3. Center for Medicare & Medicaid Services. Medicare Prescription Drug Benefit. Available from: URL:http://www.cms.hhs.gov/medicarereform/mmaregions/CMS4068P.pdf. Accessed Sept 4, 2004.
4. Schneeweiss S., Walker A.M., Glynn R.J., Maclure M., Dormuth C., and Soumerai S.B. Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 346 (2002) 822-829
5. Grootendorst P.V., Dolovich L.R., O'Brien B.J., Holbrook A.M., and Levy A.R. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ 165 (2001) 1011-1019
6. Schneeweiss S., Soumerai S.B., Maclure M., Dormuth C., Walker A.M., and Glynn R.J. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 74 (2003) 388-400
7. Marshall J.K., Grootendorst P.V., O'Brien B.J., Dolovich L.R., Holbrook A.M., and Levy A.R. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 166 (2002) 1655-1662
8. Schneeweiss S., Maclure M., Carleton B.C., Glynn R.J., and Avorn J. Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults. direct comparison of randomized and observational evaluations. BMJ 328 (2004) 560-564
9. Schneeweiss S., Dormuth C., Grootendorst P., Soumerai S., and Maclure M. Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 42 (2004) 653-660
10. Soumerai S.B., Ross-Degnan D., Avorn J., McLaughlin T., and Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 325 (1991) 1072-1077
11. Motheral B., and Fairman K.A. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 39 (2001) 1293-1304
12. Huskamp H.A., Deverka P.A., Epstein A.M., Epstein R.S., McGuigan K.A., and Frank R.G. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349 (2003) 2224-2232
13. Pinxteren B., Numans M., Lau J., de Wit N., Hungin A., Pali S., et al. Short-term treatment of gastroesophageal reflux disease. a systematic review and meta-analysis of the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative patients. J Gen Intern Med 18 (2003) 755-763
14. Richardson P., Hawkey C.J., and Stack W.A. Proton pump inhibitors. pharmacology and rationale for use in gastrointestinal disorders. Drugs 56 (1998) 307-335
15. Garnett W.R. Considerations for long-term use of proton-pump inhibitors. Am J Health Syst Pharm 55 (1998) 2268-2279
16. Castell D.O., Richter J.E., Robinson M., Sontag S.J., and Haber M.M. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 91 (1996) 1749-1757
17. Sung J.J. The role of acid suppression in the management and prevention of gastrointestinal hemorrhage associated with gastroduodenal ulcers. Gastroenterol Clin North Am 32 Suppl (2003) S11-S23
18. Lanas A., and Ferrandez A. Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 1 (2002) 245-252
19. Caro J.J., Salas M., and Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo. evidence from randomized clinical trials. Clin Ther 23 (2001) 998-1017
20. Howden C.W., Ballard E.D., and Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 22 (2002) 99-109
21. Mee A.S., and Rowley J.L. Rapid symptom relief in reflux oesophagitis. a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 10 (1996) 757-763
22. Hatlebakk J.G., Berstad A., Carling L., Svedberg L.E., Unge P., Ekstrom P., et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. results of a Scandinavian multicentre trial. Scand J Gastroenterol 28 (1993) 224-228
23. Mulder C.J., Dekker W., and Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 8 (1996) 1101-1106
24. Wong B.C.Y., Wong W.M., Yee Y.K., Hung W.K., Yip A.W.C., Szeto M.L., et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 15 (2001) 1959-1965
25. Dekkers C.P.M., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., and Humphries T.J. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer. a European multicentre study. Aliment Pharmacol Ther 13 (1999) 179-186
26. Miner Jr. P., Katz P.O., Chen Y., and Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. a five-way crossover study. Am J Gastroenterol 98 (2003) 2616-2620
27. Ghoshal U.C., Aggarwal R., and Baba C.S. Recurrent duodenal ulcer haemorrhage. a pharmacoeconomic comparison of various management strategies. Expert Opin Pharmacother 4 (2003) 1593-1603
28. PharmaCare. Changes to PharmaCare coverage criteria for proton pump inhibitors. Available from: URL:http://www.healthservices.gov.bc.ca/pharme/newsletter/PPIinformation .pdf. Accessed July 22, 2004.
29. Tejani A. The proton pump inhibitor for FH. rabeprazole (2004), Fraser Health Pharmacy News, Vancouver Summer
30. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285 (2001) 421-429
31. Anderson G.M., Kerluke K.J., Pulcins I.R., Hertzman C., and Barer M.L. Trends and determinants of prescription drug expenditures in the elderly. data from the British Columbia Pharmacare Program. Inquiry 30 (1993) 199-207
32. Williams J.I., and Young W. Inventory of studies on the accuracy of Canadian health administrative databases. Technical report (1996), Institute for Clinical Evaluative Sciences, Toronto
33. Schneeweiss S., Soumerai S.B., Glynn R.J., Maclure M., Dormuth C., and Walker A.M. Impacts of reference pricing for ACE inhibitors on drug utilization. CMAJ 166 (2002) 737-748
34. Wagner A.K., Soumerai S.B., Zhang F., and Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27 (2002) 299-309
35. Kennedy P. A guide to econometrics. 4th ed. (1998), MIT Press, Cambridge (MA) 123-125
36. Raiford D.S., Perez Gutthann S., and Garcia Rodriguez L.A. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 7 (1996) 101-104
37. Cattaruzzi C., Troncon M.G., Agostinis L., and Garcia Rodriguez L.A. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol 52 (1999) 499-502
38. Fitzmaurice G.M., Laird N.M., and Ware J.H. Applied longitudinal analysis (2004), Wiley, Hoboken
39. Freiman J.A., Chalmers T.C., Smith Jr. H., and Kuebler R.R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med 299 (1978) 690-694
40. Goodman S.N., and Berlin J.A. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 121 (1994) 200-206
41. Nelson W.W., Vermeulen L.C., Geurkink E.A., Ehlert D.A., and Reichelderfer M. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 160 (2000) 2491-2496
42. Halpern S.D., Ubel P.A., Berlin J.A., Townsend R.R., and Asch D.A. Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. J Gen Inern Med 17 (2002) 689-695
43. Avorn J. Powerful medicines. the benefits, risks, and costs of prescription drugs (2004), Knopf, New York
44. BC Stats. Migration statistics. Available from: URL:http://www.bcstats.gov.bc.ca/. Accessed March 10, 2006.
45. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 (1992) 197-203